Amidst a turbulent political climate as Republicans endeavor to enact the American Health Care Act, the shift to value-based contracts will continue due to the other market forces in play, explained Clifford Goodman, PhD, moderator at the ACO Coalition spring live meeting in Scottsdale, Arizona, and senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group.
Amidst a turbulent political climate as Republicans endeavor to enact the American Health Care Act (AHCA), the shift to value-based contracts will continue due to the other market forces in play, explained Clifford Goodman, PhD, moderator at the ACO Coalition spring live meeting in Scottsdale, Arizona, and senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group.
Transcript (slightly modified)
Do you expect Republican legislation to repeal and replace the Affordable Care Act to impact value-based reimbursement, or will gains in this area continue on regardless of new legislation?
Notwithstanding the recent political changes, including the AHCA and its ability to repeal and/or replace the Affordable Care Act, value-based reimbursement is going to continue. There are too many other market forces in play with regard to concerns about high drug prices, concerns about high prices overall for a variety of healthcare services, and the need for and focus on value for beneficiaries of all of our payer groups, provider groups, employers, and so forth.
They’re all caring about value. So, notwithstanding the extent of coverage of our populations in the United States, notwithstanding issues such as co-payments, deductibles, patient burden, and so forth, there’s going to be a continued focus on value.
I must say that it is also fueled in great measure by the continued innovation in the country. As long as we are helping to fund and provide incentives for innovation, there will be challenges about the trade-offs of benefits and costs for anyone making decisions about acquiring and accessing healthcare in the United States, so value-based contracting, outcomes-based contracting, so forth, I think will continue to evolve. That does not mean that it is a straight and narrow path to those, because in some instances it’s very difficult to implement those, but we will continue to make progress nonetheless.
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More